Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

SPRO Spero Therapeutics

Watchlist
2.015
+0.045+2.28%
Trading Session 09/30 11:28 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.070
Open
1.920
Turnover
1.62M
Low
1.890
Pre Close
1.970
Volume
818.68K
Market Cap
70.66M
P/E(TTM)
Loss
52wk High
18.840
Shares
35.07M
P/E(Static)
Loss
52wk Low
0.680
Float Cap
52.61M
Bid/Ask %
-3.23%
Historical High
23.639
Shs Float
26.11M
Volume Ratio
0.17
Historical Low
0.680
Dividend TTM
--
Div Yield TTM
--
P/B
1.97
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.14%
Amplitude
9.13%
Avg Price
1.977
Lot Size
1
Float Cap
52.61M
Bid/Ask %
-3.23%
Historical High
23.639
Shs Float
26.11M
Volume Ratio
0.17
Historical Low
0.680
Dividend TTM
--
P/B
1.97
Dividend LFY
--
Turnover Ratio
3.14%
Amplitude
9.13%
Avg Price
1.977
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
CEO: Mahadevia M.D., MBA, Ankit
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top